Sorafenib in the treatment of advanced hepatocellular carcinoma
Management of advanced hepatocellular carcinoma (HCC) is still a challenge to physicians since these patients are not candidates for surgical or ablative therapy. The disease carries a very poor prognosis with an expected survival of 4-6 months. No chemotherapeutic agent has been proven to improve t...
Main Author: | Mousa Ali |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2008-01-01
|
Series: | The Saudi Journal of Gastroenterology |
Subjects: | |
Online Access: | http://www.saudijgastro.com/article.asp?issn=1319-3767;year=2008;volume=14;issue=1;spage=40;epage=42;aulast=Mousa |
Similar Items
-
Optimal sequence of systemic therapy after sorafenib failure in patients with hepatocellular carcinoma
by: Sojung Han, et al.
Published: (2020-07-01) -
Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience
by: Omar Abdel-Rahman, et al.
Published: (2014-03-01) -
Alternative treatment strategies to sorafenib in patients with advanced hepatocellular carcinoma: a meta-analysis of randomized Phase III trials
by: Wang H, et al.
Published: (2018-08-01) -
Sorafenib in advanced hepatocellular carcinoma: current status and future perspectives
by: Hsu CH, et al.
Published: (2014-06-01) -
Research advances in transarterial chemoembolization combined with sorafenib in treatment of advanced hepatocellular carcinoma
by: WU Lei, et al.
Published: (2018-04-01)